Biggest asset in ImmuPharma's armour.23 Sep 2025 08:24
The main positive with ImmuPharma is the fact that it won't be coming to shareholders for a fundraise. Apart from the warrants, which shareholders have been aware of for the past 5-7 years, there's no further dilution. Look at the other AIM companies and the constant dilution and always at a lower price than the previous. That coupled with the fact that we have a product that has very little competition and without the nasty side effects is a massive positive. Plus there are multiple companies expressing considerable interest. Not long now!!! Good luck all. Atb Popeye.